Literature DB >> 14594761

Olanzapine effects on auditory sensory gating in schizophrenia.

Celso Arango1, Ann Summerfelt, Robert W Buchanan.   

Abstract

OBJECTIVE: New-generation antipsychotics have been proposed to normalize the P50 sensory gating index in patients with schizophrenia. In the context of a double-blind comparison of olanzapine and haloperidol, the authors examined the effect of olanzapine on P50 suppression.
METHOD: P50 measurements were obtained at baseline while patients were being treated with fluphenazine and after 12 weeks of double-blind treatment with either olanzapine (N=12) or haloperidol (N=12).
RESULTS: There were no treatment group differences in P50 amplitude, latency, or sensory gating ratio.
CONCLUSIONS: These results suggest that there is not a significant differential effect of olanzapine and haloperidol on the P50 sensory gating index in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14594761     DOI: 10.1176/appi.ajp.160.11.2066

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  12 in total

Review 1.  Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia.

Authors:  David Potter; Ann Summerfelt; James Gold; Robert W Buchanan
Journal:  Schizophr Bull       Date:  2006-02-09       Impact factor: 9.306

2.  P50 suppression and its neural generators in antipsychotic-naive first-episode schizophrenia before and after 6 months of quetiapine treatment.

Authors:  Bob Oranje; Bodil Aggernaes; Hans Rasmussen; Bjorn H Ebdrup; Birte Y Glenthøj
Journal:  Schizophr Bull       Date:  2012-01-12       Impact factor: 9.306

3.  Comparing Pharmacological Modulation of Sensory Gating in Healthy Humans and Rats: The Effects of Reboxetine and Haloperidol.

Authors:  Louise Witten; Jesper Frank Bastlund; Birte Y Glenthøj; Christoffer Bundgaard; Björn Steiniger-Brach; Arne Mørk; Bob Oranje
Journal:  Neuropsychopharmacology       Date:  2015-07-01       Impact factor: 7.853

Review 4.  Music therapy for people with schizophrenia and schizophrenia-like disorders.

Authors:  Monika Geretsegger; Karin A Mössler; Łucja Bieleninik; Xi-Jing Chen; Tor Olav Heldal; Christian Gold
Journal:  Cochrane Database Syst Rev       Date:  2017-05-29

Review 5.  Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures.

Authors:  Bruce I Turetsky; Monica E Calkins; Gregory A Light; Ann Olincy; Allen D Radant; Neal R Swerdlow
Journal:  Schizophr Bull       Date:  2006-11-29       Impact factor: 9.306

6.  Olanzapine improves deficient sensory inhibition in DBA/2 mice.

Authors:  Johanna K Simosky; Robert Freedman; Karen E Stevens
Journal:  Brain Res       Date:  2008-07-25       Impact factor: 3.252

Review 7.  Neurophysiological endophenotypes across bipolar and schizophrenia psychosis.

Authors:  Gunvant K Thaker
Journal:  Schizophr Bull       Date:  2008-05-22       Impact factor: 9.306

Review 8.  Biomarkers of bipolar disorder: specific or shared with schizophrenia?

Authors:  Frank Bellivier; Pierre Alexis Geoffroy; Jan Scott; Franck Schurhoff; Marion Leboyer; Bruno Etain
Journal:  Front Biosci (Elite Ed)       Date:  2013-06-01

Review 9.  Translational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation.

Authors:  J Smucny; K E Stevens; A Olincy; J R Tregellas
Journal:  Transl Psychiatry       Date:  2015-06-23       Impact factor: 6.222

10.  Non-invasive electroencephalographical (EEG) recording system in awake monkeys.

Authors:  Tomoya Nakamura; Trong Ha Dinh; Makoto Asai; Hiroshi Nishimaru; Jumpei Matsumoto; Yusaku Takamura; Etsuro Hori; Sokichi Honda; Hiroshi Yamada; Takuma Mihara; Mitsuyuki Matsumoto; Hisao Nishijo
Journal:  Heliyon       Date:  2020-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.